Pasvolsky, Oren
Milton, DenĂ¡i R.
Rauf, Mikael
Ghanem, Sassine http://orcid.org/0000-0001-7295-0978
Masood, Adeel
Mohamedi, Ali H.
Tanner, Mark R.
Bashir, Qaiser
Srour, Samer
Saini, Neeraj
Lin, Paul
Ramdial, Jeremy
Nieto, Yago
Tang, Guilin http://orcid.org/0000-0002-9482-4806
Lee, Hans C. http://orcid.org/0000-0001-8545-3292
Patel, Krina K.
Kebriaei, Partow
Thomas, Sheeba K.
Weber, Donna M.
Orlowski, Robert Z.
Rezvani, Katy
Champlin, Richard
Shpall, Elizabeth J.
Lin, Pei
Qazilbash, Muzaffar H. http://orcid.org/0000-0003-2876-2886
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 1 March 2023
Revised: 14 April 2023
Accepted: 19 April 2023
First Online: 3 May 2023
Competing interests
: MHQ has research funding from Janssen, NexImmune, and Angiocrine. QB has research funding from Stemline, GlaxoSmithKline, Takeda, and Acrotech, and consulting with Purdue, Amgen, Kite, and Wolters Kluwer. PL has a license and research agreement with Takeda Pharmaceuticals. YN has research funding from Affimed, AstraZeneca, and Securabio and consulting from Affimed. HCL has consulting with Bristol Myers Squibb, Celgene, Genentech, Karyopharm, Legend Biotech, GlaxoSmithKline, Sanofi, Pfizer, Monte Rosa Therapeutics, Oncopeptides, and Takeda Pharmaceuticals and research funding from Amgen, Bristol Myers Squibb, Janssen, GlaxoSmithKline, Regeneron, and Takeda Pharmaceuticals. KKP has research funding from Abbvie, Bristol Myers Squibb, Celgene, Takeda, Precision Bio, Cellectis, Allogene, and Nektar and consulting with Bristol Myers Squibb, Celgene, Janssen, Pfizer, Oncopeptides, Arcellx, Cellectis, and Karyopharm. PK has research funding from Amgen and Ziopharm and consulting with Jazz, Kite, and Pfizer. SKT has research funding from Bristol Myers Squibb, Genentech, X4 Pharma, Cellectar, and Ascentage. RZO is founder of Asylia Therapeutics, has research funding from Biotheryx, Asylia Therapeutics, CARsgen, Celgene, Exelixis, and Heidelberg Pharma and consulting with Biotheryx, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Meridian Therapeutics, Monte Rosa Therapeutics, Neoleukin Therapeutics, Oncopeptides, Regeneron, Sanofi-Aventis, and Takeda. KR, EJS, and The University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Takeda Pharmaceutical and Affimed GmbH. KR participates on the Scientific Advisory Board for GemoAb, AvengeBio, Virogin Biotech, GSK, Caribou Biosciences, Navan Technologies and Bayer. EJS has consulting with Bayer, Novartis, Navan, Magenta, Adaptimmune, Mesoblast, and Axio. The other authors have not declared a competing interests.